Document Detail

Enhancement of antitumor vaccine in ablated hepatocellular carcinoma by high-intensity focused ultrasound.
MedLine Citation:
PMID:  20653069     Owner:  NLM     Status:  MEDLINE    
AIM: To investigate whether tumor debris created by high-intensity focused ultrasound (HIFU) could trigger antitumor immunity in a mouse hepatocellular carcinoma model.
METHODS: Twenty C57BL/6J mice bearing H22 hepatocellular carcinoma were used to generate antitumor vaccines. Ten mice underwent HIFU ablation, and the remaining 10 mice received a sham-HIFU procedure with no ultrasound irradiation. Sixty normal mice were randomly divided into HIFU vaccine, tumor vaccine and control groups. These mice were immunized with HIFU-generated vaccine, tumor-generated vaccine, and saline, respectively. In addition, 20 mice bearing H22 tumors were successfully treated with HIFU ablation. The protective immunity of the vaccinated mice was investigated before and after a subsequent H22 tumor challenge. Using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, the cytotoxicity of splenic lymphocytes co-cultured with H22 cells was determined in vitro before the tumor challenge, and tumor volume and survival were measured in vivo after the challenge in each group. The mechanism was also explored by loading the vaccines with bone marrow-derived dendritic cells (DCs).
RESULTS: Compared to the control, HIFU therapy, tumor-generated and HIFU-generated vaccines significantly increased cytolytic activity against H22 cells in the splenocytes of the vaccinated mice (P < 0.001). The tumor volume was significantly smaller in the HIFU vaccine group than in the tumor vaccine group (P < 0.05) and control group (P < 0.01). However, there was no tumor growth after H22 rechallenge in the HIFU therapy group. Forty-eight-day survival rate was 100% in mice in the HIFU therapy group, 30% in both the HIFU vaccine and tumor vaccine groups, and 20% in the control group, indicating that the HIFU-treated mice displayed significantly longer survival than the vaccinated mice in the remaining three groups (P < 0.001). After bone marrow-derived DCs were incubated with HIFU-generated and tumor-generated vaccines, the number of mature DCs expressing MHC-II(+), CD80(+) and CD86(+) molecules was significantly increased, and interleukin-12 and interferon-gamma levels were significantly higher in the supernatants when compared with immature DCs incubated with mouse serum (P < 0.001). However, no differences of the number of mature DCs and cytokine levels were observed between the HIFU-generated and tumor-generated vaccines (P > 0.05).
CONCLUSION: Tumor debris remaining after HIFU can improve tumor immunogenicity. This debris releases tumor antigens as an effective vaccine to develop host antitumor immune response after HIFU ablation.
Ying Zhang; Jian Deng; Jun Feng; Feng Wu
Related Documents :
10760879 - From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate-base...
20634349 - Vaccination against the extra domain-b of fibronectin as a novel tumor therapy.
12901569 - T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience...
18294279 - Co-administration of carcinoembryonic antigen and hiv tat fusion protein with cpg-oligo...
19335279 - Dcvax-brain and dc vaccines in the treatment of gbm.
20845479 - Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer...
18194079 - Safety and immunogenicity of a new hepatitis b vaccine for the protection of patients w...
11529299 - The tuberculin skin test in relation to immunological in vitro reactions in bcg-vaccina...
10669329 - Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/r...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  16     ISSN:  2219-2840     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-23     Completed Date:  2010-12-17     Revised Date:  2014-05-20    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  3584-91     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cancer Vaccines / therapeutic use*
Carcinoma, Hepatocellular / metabolism,  pathology,  therapy*
Combined Modality Therapy
Dendritic Cells / metabolism
Disease Models, Animal
High-Intensity Focused Ultrasound Ablation*
Interferon-gamma / metabolism
Interleukin-12 / metabolism
Liver Neoplasms / metabolism,  pathology,  therapy*
Mice, Inbred C57BL
Treatment Outcome
Reg. No./Substance:
0/Cancer Vaccines; 187348-17-0/Interleukin-12; 82115-62-6/Interferon-gamma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Correlation between pre-miR-146a C/G polymorphism and gastric cancer risk in Chinese population.
Next Document:  Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.